title: A phase II study of concomitant chemoradiotherapy for laryngeal carcinoma using carboplatin.
abstract: OBJECTIVE
  We conducted a phase II study of concomitant chemoradiotherapy with carboplatin for laryngeal carcinoma.
  
  
  METHODS
  Sixty-four patients with stage II-IV (stage II, 36; III, 19; IV 9) laryngeal carcinoma were treated with concomitant administration of carboplatin (CBDCA) during radiotherapy (CRT group) between 1991 and 1994. There were 36 supraglottic, 25 glottic, and 3 subglottic carcinomas. Patients with stage II and stage III-IV received intravenous CBDCA of 100 mg/m2 and 120 mg/m2 once a week, respectively. Tumor response was assessed at 40 Gy in 16 fractions to select the patients suitable for total laryngectomy or radical radiotherapy of 65 Gy in 26 fractions in 6.5 weeks. The treatment results were compared with the historical control consisting of 56 patients consecutively treated from 1988 to 1990 without chemotherapy (RT group). The two studies were comparable with regard to patient characteristics, including age distribution, gender, tumor location, size, and clinical stage.
  
  
  RESULTS
  The actuarial 5-year survival rate was 80.3% for the CRT group and 81.3% for the RT group. A favorable response (complete response or partial response) at 40 Gy was observed in 87.5% of the patients of the CRT group and in 62.5% of the patients of the RT group (chi2 = 7.566, p < 0.01). The actuarial 5-year larynx preservation rate for the CRT group (75%) was significantly higher than that for the RT group (57%) in patients with T2 supraglottic carcinoma (p < 0.05). There was no difference in the larynx preservation rate between the two treatment arms for any T stage of glottic carcinomas.
  
  
  CONCLUSIONS
  CRT using carboplatin improved the tumor response at 40 Gy and consequently achieved a higher larynx preservation rate for T2 supraglottic carcinoma. A clinical randomized trial is indicated to certify the findings of this phase II study.
authors.affiliation: Department of Radiology, School of Dentistry, Hokkaido University, Sapporo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nishioka
authors.forename: H
authors.initials: H
authors.lastname: Shirato
authors.forename: S
authors.initials: S
authors.lastname: Fukuda
authors.forename: T
authors.initials: T
authors.lastname: Arimoto
authors.forename: T
authors.initials: T
authors.lastname: Kamada
authors.forename: Y
authors.initials: Y
authors.lastname: Furuta
authors.forename: S
authors.initials: S
authors.lastname: Nishino
authors.forename: Y
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: T
authors.initials: T
authors.lastname: Kitahara
authors.forename: K
authors.initials: K
authors.lastname: Kagei
authors.forename: Y
authors.initials: Y
authors.lastname: Inuyama
authors.forename: K
authors.initials: K
authors.lastname: Miyasaka
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin